In spite of excluding the patients with a KRAS mutation in their cancer from receiving anti-EGFR therapy, the response rates in the patients with WT KRAS are of the order of 17%–60% [6, 13, 69, 70, 73–75]. This evidence concerns the gene KRAS and cancer.